Dr. Changqing Su is currently a professor & Ph.D. tutor at the Eastern Hepatobiliary Surgical Hospital of Second Military Medical University and a staff scientist at the National Center of Liver Cancer, Shanghai, China. He is also an expert panel member of Shanghai & National Natural Scientific Foundation, a member of the Chinese Anti-Cancer Association and a member of Jiangsu Center for Collaboration and Innovation of Cancer Biotherapy, China. He received his Bachelor of Medicine at Xuzhou Medical University in 1987, Master of Medicine at Anhui Medical University in 1990, and completed his Ph.D. in Cellular and Molecular Biology at School of Life Sciences, Nanjing Normal University in 2000. He pursued postdoctoral training at the Eastern Hepatobiliary Surgical Hospital of SecondMilitaryMedical University from 2001 to 2003 under the guidance of cooperation supervisor, Dr. Mengchao Wu, an academician of Chinese Academy of science. In 2009, he was a visiting scientist at Department of Laboratory Medicine and Experimental Pathology in Mayo Clinic, Rochester, USA. During 1990-2000, Dr. Changqing Su worked in pathological diagnosis and research of cancer cell cycle regulation and metastasis at the National Cancer Center of Chinese People’s Liberation Army (PLA). With his findings in the molecular mechanisms of p16 gene inactivation and its induction of cancer cell cycle arrest and apoptosis, he acquired a grant from the National Natural Scientific Foundation of China, and was recognized by PLA as an outstanding talent of science and technology (1999) and a major medical contributor for medical science and technology (2000). Since 2001, he has been working at the Eastern Hepatobiliary Surgical Hospital, National Center of Liver Cancer, Second Military Medical University, Shanghai, China. As an academic leader and director of a molecular oncological research and innovation team for liver cancer, he investigated into cancer cell cycle regulation and target biotherapy in hepatobiliary cancer, and made a series of research achievements, some of which were the landmark achievements of the First National Progress Prize in Science and Technology (2012) and the First Prize in Military Medical Achievement Award (2014).With his contributions in the target gene-viral therapy for cancers with tumor-selectively replicating oncolytic adenovirus, hewas awarded the title “Shanghai outstanding academic leader” in 2013 and acquired 2 projects from the National Natural Scientific Foundation of China. He has been majoring in anti-tumor novel drug research and development, and screened out a novel matrine derivative WM130, which can inhibit activation of hepatic stellate cells, attenuate liver fibrosis and prevent hepatic carcinogenesis.With his important findings, he was supported by the National Significant Science and Technology Major Projects of New Drugs Creation. He also obtained funds from the National Significant Science and Technology Special Projects of Major Infectious Disease Prevention and Control, the State 863 High Technology Research & Development Project of China, and the National Key Scientific Research Projects. His current interests include not only the modification effect of cancer cell-secreted microRNAs on stromal cells to construct microenviroment for cancer metastasis, but also the novel target strategy for effectively impeding hepatic fibrosis and preventing carcinogenesis with human sulfatase 1 gene to desulfate cell surface heparan sulfate proteoglycans and negatively modulate multiple growth factor signaling pathways. Dr. Su is the author of more than 290 scientific articles and 5 book chapters. He is also an editorial board member of “Cancer Letters”, “Chinese clinical oncology”, “Chinese Pharmacological Bulletin” and “Journal of Diagnostics Concepts & Practice”, and a reviewer of a number of peer-reviewed journal publications. He has 6 China national invention patents and Patent Cooperation Treaty (PCT), some of which have been licensed to several pharmaceutical companies. This Special Issue Hepatobiliary Cancer for “Cancer Letters”addresses the critical researches of hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer and liver metastatic carcinoma from etiology, epidemiology to clinical therapeutic approaches, from carcinogenesis, signaling transduction to molecular diagnosis, from cellular heterogeneity, molecular evolution to personalized therapy. The reviews are expected to provide a
